Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 05, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The material change reported is a transfer of 19,565 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on September 1, 2006, and was advised to the Company on September 4, 2006.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. It notes that the GSK Trust is a discretionary trust for current and former employees, and that three directors (Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop) are interested in the shares held in the trust similarly to other employees.
Key Facts for Investor Verification
- Transaction Type: Transfer of shares from an employee trust to plan participants.
- Volume: 19,565 Ordinary Shares.
- Plan Involved: SmithKline Beecham Employee Share Option Plan 1991.
- Directors Involved: Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop hold interests in the trust but are not individually identified as the recipients of this specific transfer.
- Regulatory Basis: Notification made under Disclosure Rule 3.1.4R(1)(b).